Richard G. Moore
YOU?
Author Swipe
View article: Effects of a novel proteasome inhibitor, UR238 on the tumor immune microenvironment and growth in epithelial ovarian cancer
Effects of a novel proteasome inhibitor, UR238 on the tumor immune microenvironment and growth in epithelial ovarian cancer Open
High-grade serous ovarian cancer (HGSOC) is a deadly gynecologic malignancy, often diagnosed at an advanced stage and most patients will experience recurrence and resistance to platinum-based chemotherapy. While there are few targeted ther…
View article: PSP-0119: Targeted IRAK4 Degradation as a Novel Therapeutic Strategy for FLT3-Mutant AML
PSP-0119: Targeted IRAK4 Degradation as a Novel Therapeutic Strategy for FLT3-Mutant AML Open
Acute Myeloid Leukemia (AML) is a life-threatening hematologic malignancy. Despite recent therapeutic advances, rising incidence rates emphasize the urgent need for identification of new targets and therapies. Roles of interleukin receptor…
View article: The utility of the novel biomarker HE4 for monitoring epithelial ovarian cancer during PARP inhibitor treatment
The utility of the novel biomarker HE4 for monitoring epithelial ovarian cancer during PARP inhibitor treatment Open
A total of 102 patients with 103 treatment periods and 1554 evaluable serum samples were evaluated. Of these patients, 55 (53.9%) experienced a change in disease status while receiving PARP inhibitor treatment. An analysis using increases …
View article: A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO
A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO Open
In OVARIO, median OS was 61.1 months in the overall population. Safety was consistent with known safety profiles of niraparib and bevacizumab as monotherapies.
View article: Dostarlimab and niraparib in primary advanced ovarian cancer
Dostarlimab and niraparib in primary advanced ovarian cancer Open
View article: IL-1β/IRAK4 Axis Promotes Ovarian Tumor Development at the Mesothelium Injury Sites
IL-1β/IRAK4 Axis Promotes Ovarian Tumor Development at the Mesothelium Injury Sites Open
Epithelial ovarian cancer (EOC) cells seed at mesothelial inflammation or injury sites. Lack of animal models recapitulating tumor cells seeding at inflamed sites in EOC hinders mechanistic studies and therapy developments. Here, we develo…
View article: Gestión de procesos académicos y su influencia en la satisfacción del estudiante en una universidad privada que implementa el modelo por competencias
Gestión de procesos académicos y su influencia en la satisfacción del estudiante en una universidad privada que implementa el modelo por competencias Open
View article: Endometrioid adenocarcinoma of the colon arising from rare malignant transformation of extra-gonadal endometrioma
Endometrioid adenocarcinoma of the colon arising from rare malignant transformation of extra-gonadal endometrioma Open
We report a case of malignant intestinal endometriosis. There is limited evidence to support a standardized approach to treatment due to the rare nature of this disease; the patient opted for observation. By understanding the presentation,…
View article: The NF-κB-HE4 axis: A novel regulator of HE4 secretion in ovarian cancer
The NF-κB-HE4 axis: A novel regulator of HE4 secretion in ovarian cancer Open
Ovarian cancer is the leading cause of death among gynecologic malignancies. Despite recent advancements in targeted therapies such as PARP inhibitors, recurrence is common and frequently resistant to existing therapies. A powerful diagnos…
View article: First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial Open
PURPOSE Lenvatinib plus pembrolizumab (len + pembro) significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in previously treated advanced or recurrent endometrial cancer (aEC) in the phase III…
View article: Identification of circulating tumor cells captured by the FDA-cleared Parsortix® PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations
Identification of circulating tumor cells captured by the FDA-cleared Parsortix® PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations Open
Circulating Tumor Cells (CTCs) may serve as a non-invasive source of tumor material to investigate an individual’s disease in real-time. The Parsortix ® PC1 System, the first FDA-cleared medical device for the capture and harvest of CTCs f…
View article: In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemia
In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemia Open
View article: A whole food, plant-based randomized controlled trial in metastatic breast cancer: feasibility, nutrient, and patient-reported outcomes
A whole food, plant-based randomized controlled trial in metastatic breast cancer: feasibility, nutrient, and patient-reported outcomes Open
View article: Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – a plain language summary
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – a plain language summary Open
WHAT IS THIS SUMMARY ABOUT?: This PLSP provides a short summary of an original scientific article that presented results from the PRIMA study after 3.5 years of follow-up time. The original article was published in the European Journal of …
View article: A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes
A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes Open
Purpose Breast cancer treatment is associated with weight gain, and obesity and its related cardiometabolic and hormonal risk factors have been associated with poorer outcomes. Dietary intervention may address these risk factors, but limit…
View article: Forchlorfenuron-Induced Mitochondrial Respiration Inhibition and Metabolic Shifts in Endometrial Cancer
Forchlorfenuron-Induced Mitochondrial Respiration Inhibition and Metabolic Shifts in Endometrial Cancer Open
Forchlorfenuron (FCF) is a widely used plant cytokinin that enhances fruit quality and size in agriculture. It also serves as a crucial pharmacological tool for the inhibition of septins. However, the precise target of FCF has not yet been…
View article: Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer
Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer Open
View article: Normal Risk Ovarian Screening Study: 21-Year Update
Normal Risk Ovarian Screening Study: 21-Year Update Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: A Whole Food, Plant-Based Randomized Controlled Trial in Metastatic Breast Cancer: Feasibility, Nutrient, and Patient-Reported Outcomes
A Whole Food, Plant-Based Randomized Controlled Trial in Metastatic Breast Cancer: Feasibility, Nutrient, and Patient-Reported Outcomes Open
View article: A Whole-Food, Plant-Based Randomized Controlled Trial in Metastatic Breast Cancer: Weight, Cardiometabolic, and Hormonal Outcome
A Whole-Food, Plant-Based Randomized Controlled Trial in Metastatic Breast Cancer: Weight, Cardiometabolic, and Hormonal Outcome Open
Purpose Breast cancer treatment is associated with weight gain, and obesity and its related cardiometabolic and hormonal risk factors have been associated with poorer outcomes. Dietary intervention may address these risk factors, but limit…
View article: LBA43 Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial
LBA43 Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial Open
View article: 748P Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
748P Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775 Open
View article: Characterization of tumor response with lenvatinib plus pembrolizumab in study 309/KEYNOTE-775 (177)
Characterization of tumor response with lenvatinib plus pembrolizumab in study 309/KEYNOTE-775 (177) Open
View article: Malignant transformation of mature cystic teratoma involving bowel: A case report
Malignant transformation of mature cystic teratoma involving bowel: A case report Open
Mature cystic teratomas are common benign neoplasms of the ovary. These tumors rarely undergo malignant transformation, the most frequent transformation is to a squamous cell carcinoma. Malignant transformation carries a poor prognosis. He…
View article: Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1
Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1 Open
Small-molecule inhibitors of PD-L1 are postulated to control immune evasion in tumors similar to antibodies that target the PD-L1/PD-1 immune checkpoint axis. However, the identity of targetable PD-L1 inducers is required to develop small-…
View article: Characterization of Patients with Endometrial Cancer and Low-Volume Nodal Disease
Characterization of Patients with Endometrial Cancer and Low-Volume Nodal Disease Open
Background: Isolated tumor cells (ITCs) are deposits measuring ≤0.2 mm, whereas micro metastasis (MM) measures >0.2 to ≤2 mm.The significance of these findings in endometrial cancer remains controversial.We sought to determine whether pati…
View article: Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer Open
View article: In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemia
In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemia Open
Acute myeloid leukemia (AML) is fatal in majority of adults. Identification of new therapeutic targets and their pharmacologic modulators are needed to improve outcomes. Previous studies had shown that immunization of rabbits with normal p…
View article: Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775 Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: Supplementary Data from Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
Supplementary Data from Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial Open
Supplementary Data from Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial